As of Q4'25, RXRX reported R&D Expenses of USD 95.94M and SG&A Expenses of USD 33.66M, marking a notable decrease from the previous quarters. This latest data point reflects a significant reduction in both operating expense categories compared to the peaks observed earlier in 2025. Over the period from Q1'23 to Q4'25, RXRX's operating expenses exhibited a general upward trend, with R&D Expenses rising sharply to a high of USD 129.63M in Q1'25 before declining in the subsequent quarters. SG&A Expenses followed a similar pattern, peaking at USD 77.19M in Q4'24 and then trending downward. The data suggests a period of accelerated investment through 2024 and early 2025, followed by a strategic pullback in spending towards the end of the observed timeframe.